BioRestorative TherapiesBRTX
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7% more funds holding
Funds holding: 14 [Q1] → 15 (+1) [Q2]
0.78% less ownership
Funds ownership: 4.07% [Q1] → 3.3% (-0.78%) [Q2]
18% less capital invested
Capital invested by funds: $502K [Q1] → $412K (-$89.9K) [Q2]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for BRTX.
Financial journalist opinion
Based on 3 articles about BRTX published over the past 30 days









